Kodiak Sciences Inc (KOD):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10632)
◆英語タイトル:Kodiak Sciences Inc (KOD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10632
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjugate technology, which is a proprietary product platform that combines biologics design with next generation phosphorylcholine biopolymers. The company offers KSI 301 an anti-VEGF biologic development, which offers potential for patients to remain on mechanism for a longer interval between consecutive intravitreal injections. It commercializes technology to both biopharmaceuticals and small molecules companies. Kodiak Sciences is headquartered in Palo Alto, California, the US.

Kodiak Sciences Inc (KOD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kodiak Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kodiak Sciences Raises USD34 Million in Series B Financing 10
Kodiak Sciences Raises USD34 Million in Venture Financing 11
Partnerships 12
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 12
Lonza Enters into Agreement with Kodiak Sciences 13
Equity Offering 14
Kodiak Sciences Prices IPO of Shares for USD90 Million 14
Debt Offering 16
Kodiak Sciences Raises USD33 Million in Private Placement of Notes 16
Kodiak Sciences Raises USD10 Million in Private Placement of Notes 17
Kodiak Sciences Inc – Key Competitors 18
Kodiak Sciences Inc – Key Employees 19
Kodiak Sciences Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Nov 16, 2018: Kodiak Sciences announces third quarter 2018 financial results and recent business highlights 21
Corporate Communications 23
Sep 17, 2018: Kodiak Sciences names Jason Ehrlich as Chief Medical Officer and Chief Development Officer 23
Jul 18, 2018: Kodiak Sciences names Bassil I. Dahiyat, Robert A. Profusek and Richard S. Levy as board directors 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kodiak Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kodiak Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kodiak Sciences Raises USD34 Million in Series B Financing 10
Kodiak Sciences Raises USD34 Million in Venture Financing 11
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 12
Lonza Enters into Agreement with Kodiak Sciences 13
Kodiak Sciences Prices IPO of Shares for USD90 Million 14
Kodiak Sciences Raises USD33 Million in Private Placement of Notes 16
Kodiak Sciences Raises USD10 Million in Private Placement of Notes 17
Kodiak Sciences Inc, Key Competitors 18
Kodiak Sciences Inc, Key Employees 19

List of Figures
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kodiak Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Kodiak Sciences Inc (KOD):製薬・医療:M&Aディール及び事業提携情報(Kodiak Sciences Inc (KOD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆